View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2020

Alexion to study Ultomiris for Covid-19 treatment

Alexion Pharmaceuticals intends to assess its blood disorder drug Ultomiris (ravulizumab-cwvz) to treat adult Covid-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS).

Alexion Pharmaceuticals intends to assess its blood disorder drug Ultomiris (ravulizumab-cwvz) to treat adult Covid-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS).

The US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for the drug in severe Covid-19 indication.

Ultomiris is a long-acting C5 complement inhibitor. The biologic medicine has approvals to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and complement-mediated thrombotic microangiopathy.

The new trial is designed to assess the drug’s effect on survival, mechanical ventilation duration, and hospital stay when compared to best supportive care.

Starting in May, the open-label, randomised, controlled study is set to recruit around 270 patients in countries with high Covid-19 cases.

The primary endpoint is survival at day 29, while secondary endpoints include the need for mechanical ventilation, oxygenation, ICU stay and hospitalisation duration, and safety.

A four-week treatment period will be followed by safety monitoring for three months.

Alexion Pharmaceuticals Research & Development executive vice-president and head John Orloff said: “Based on early anecdotal information available from compassionate use cases in multiple countries, we are launching a controlled clinical trial to evaluate the potential of Ultomiris in mitigating the severe pneumonia and lung injury caused by the virus.

“As we move quickly to initiate this programme, we also remain committed to serving the patients who currently rely on our medicines and providing continuous supply to these patients.”

The company noted that independent investigators are interested in assessing the potential of C5 inhibition for severe Covid-19 pneumonia.

While several independent studies are ongoing, Alexion believes that a controlled clinical programme is necessary to determine C5 inhibition’s impact with Ultomiris.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU